ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET

Company Participants

Lisa Wilson - IR
Nikhil Lalwani - President, CEO & Director
Christopher Mutz - SVP, Head, Rare Diseases
Stephen Carey - CFO & SVP

Conference Call Participants

Les Sulewski - Truist Securities
Gary Nachman - Raymond James & Associates
Vamil Divan - Guggenheim Securities
Oren Livnat - H.C. Wainwright & Co.
Tim Chiang - Capital One

Operator

Good day, everyone, and welcome to today's ANI Pharmaceuticals, Inc. Second Quarter 2024 Earnings Results Call. [Operator Instructions].

It is now my pleasure to turn the conference over to Lisa Wilson. Please go ahead, ma'am.

Lisa Wilson

Thank you, Katie. Welcome to ANI Pharmaceuticals Q2 2024 earnings results call. This is Lisa Wilson of Insight Communications, Investor Relations for ANI. With me on today's call are Nikhil Lalwani, President, and Chief Executive Officer; Steve Carey, Chief Financial Officer; and Chris Mutz, Senior Vice President and Head of ANI's rare disease business.

You can also access the webcast of this call through the investor section of the ANI website at anipharmaceuticals.com. Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act.

These forward-looking statements are based on information available to ANI Pharmaceuticals management as of today and involve risks and uncertainties, including those noted in our press release issued this morning and our filings with the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements.

ANI specifically disclaims any intent or obligation to update these forward-looking statements except as required by law. The archived webcast will be available for 30 days on our website, anipharmaceuticals.com. For the benefit of those who may be listening to the replay or archived webcast, this call is held and recorded on August 6, 2024. Since then, ANI may have made announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filings.

And with that, I'll turn the call over to Nikhil Lalwani.

Nikhil Lalwani

Thanks, to Lisa. Good morning, everyone, and thank you for joining our second quarter earnings call. We are delighted with ANI's accomplishments in the second quarter. We achieved both record revenues and a major milestone in our ongoing efforts to expand the scope and scale of our rare disease business with our proposed acquisition of Alimera Sciences.